IDH1 or IDH2 mutations are early events in gliomagenesis, are negatively associated with PTEN mutation and EGFR amplification, and in the astrocytoma sub-type of glioma, are positively associated with TP53 mutation (Gupta et al., 2011, Reitman and Yan, 2010). Here, IDH1 is linked to central nervous system cancer.